Wednesday, November 18, 2026 The HN.9 randomized Phase II Study of Cisplatin plus Radiotherapy versus Durvalumab plus Radiotherapy followed by Adjuvant Durvalumab versus Durvalumab plus Radiotherapy followed by Adjuvant Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Locoregionally Advanced Oropharyngeal Squamous Cell Cancer (LA-OSCC) has permanently closed.The study evaluated a cisplatin-free treatment approach combining immunotherapy (durvalumab) with radiation therapy in patients with intermediate-risk, HPV-positive, locally advanced oropharyngeal squamous cell carcinoma. Researchers investigated whether replacing the standard chemotherapy drug cisplatin with immunotherapy could reduce severe long-term side effects while maintaining the same event free survival benefit.The study found that the chemotherapy-sparing combination did not improve event-free survival compared to standard treatment. No new safety signals were identified. While specific toxicities differed between treatment arms, overall quality-of-life outcomes — including swallowing function — were similar between groups and consistent with findings from previous trials.The primary publication has not been completed and results were presented at ASCO: https://www.asco.org/abstracts-presentations/260979.Final analysis of the investigator-initiated randomized study of anti–PD-L1 durvalumab (durva) with radiation versus chemoradiation (CRT) for intermediate-risk HPV-positive (HPV+) locally advanced oropharyngeal squamous cell carcinoma (LA-OPSCC): Canadian Cancer Trials Group (CCTG) HN.9 (EORTC 1740-HNCG). Clinicaltrials.gov Results Reporting - NCT03410615 at clinicaltrials.gov